Ivafy 5mg Tablet contains Ivabradine, a selective inhibitor of the If current in the sinoatrial node, used primarily for the management of chronic stable angina pectoris and heart failure. Ivabradine acts by reducing the heart rate without affecting myocardial contractility or intracardiac conduction, thereby decreasing myocardial oxygen demand and improving exercise tolerance in patients with angina. It is indicated for patients with stable angina who are in sinus rhythm with a resting heart rate above 70 beats per minute and for patients with chronic heart failure with reduced ejection fraction who remain symptomatic despite optimal standard therapy. Ivafy 5mg is administered orally, with dosage individualized based on heart rate response and clinical condition. Common side effects include bradycardia, hypertension, atrial fibrillation, and visual disturbances such as phosphenes. Contraindications include acute decompensated heart failure, sinoatrial block, severe hypotension, and concomitant use with strong CYP3A4 inhibitors. Ivafy should be used cautiously in patients with conduction abnormalities or pacemaker dependence. Regular monitoring of heart rate and rhythm is recommended during therapy. Ivafy 5mg Tablet offers a targeted approach to heart rate reduction, improving symptoms and quality of life in selected cardiovascular patients.